Eli Lilly and Company (NYSE:LLY) Shares Climb 2.9% – Time to Buy?

Eli Lilly and Company (NYSE:LLY) traded up 2.9% during mid-day trading on Thursday. The stock traded as high as $1,321.21 and last traded at $1,308.2070. Approximately 2,641,545 shares traded hands during mid-day trading, a decline of 10% from the average session volume of 2,943,044 shares. The stock had previously closed at $1,270.75.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly broke ground on a new $5 billion manufacturing facility in Virginia, part of a more than $50 billion U.S. production expansion. The site will be Lilly’s first fully integrated facility producing both active pharmaceutical ingredients and finished medicines, including capacity for next-generation cancer treatments, and is expected to create 650 jobs. The investment should improve long-term supply capacity and reduce manufacturing bottlenecks. Lilly Richmond manufacturing facility
• Positive Sentiment: Lilly and UAE-based Mubadala Bio reportedly agreed to cooperate on packaging, logistics and advanced pharmaceutical contract manufacturing for GLP-1 medicines in Abu Dhabi. Local infrastructure could support international distribution of Mounjaro and other weight-loss products while expanding Lilly’s regional presence. Lilly Mubadala Bio GLP-1 agreement
• Neutral Sentiment: Investor attention remains elevated after Lilly recently reached a record high. Strong demand for its obesity portfolio, including Zepbound and Mounjaro, remains the central growth narrative, but the stock’s premium valuation leaves it particularly sensitive to earnings and guidance.
• Negative Sentiment: Analysts expect Lilly’s upcoming third-quarter earnings to decline, and a Zacks preview says the company lacks the typical combination of estimate revisions and earnings momentum associated with a likely beat. This raises the risk of disappointment after the stock’s strong run. Eli Lilly Q3 earnings preview
• Negative Sentiment: Lilly’s recent revenue growth has been driven primarily by higher volume rather than pricing: second-quarter sales rose 48% while medicine volume increased 60%, but average prices fell 13%. Continued price pressure could weigh on margins and make future growth increasingly dependent on prescription volume. Lilly revenue growth and pricing
• Negative Sentiment: Novo Nordisk’s CagriSema reportedly produced 25% weight loss in women, highlighting a potentially stronger competing obesity treatment and reinforcing competitive pressure on Lilly’s GLP-1 franchise.

Analyst Ratings Changes

Several research firms recently commented on LLY. Cantor Fitzgerald raised their target price on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an “overweight” rating in a report on Thursday, October 8th. Leerink Partners boosted their target price on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a report on Wednesday. Morgan Stanley lifted their target price on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. UBS Group set a $1,376.00 price target on Eli Lilly and Company in a research report on Friday, August 7th. Finally, Weiss Ratings raised Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,317.93.

Eli Lilly and Company Trading Up 2.9%

The firm has a market cap of $1.23 trillion, a PE ratio of 43.90, a PEG ratio of 1.71 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The business has a 50-day moving average price of $1,184.78 and a two-hundred day moving average price of $1,119.15.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same period in the prior year, the firm earned $6.31 EPS. The firm’s quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts forecast that Eli Lilly and Company will post 33.56 EPS for the current year.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 in the last 90 days. 0.14% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently bought and sold shares of the stock. Maseco LLP raised its stake in Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after buying an additional 28 shares in the last quarter. Marshall & Sterling Wealth Advisors Inc. lifted its position in Eli Lilly and Company by 60.0% in the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after buying an additional 15 shares in the last quarter. AlphaCentric Advisors LLC bought a new stake in Eli Lilly and Company in the first quarter worth $42,000. Caitlin John LLC acquired a new position in Eli Lilly and Company in the 2nd quarter valued at $64,000. Finally, IMG Wealth Management Inc. raised its stake in Eli Lilly and Company by 500.0% during the 2nd quarter. IMG Wealth Management Inc. now owns 60 shares of the company’s stock valued at $72,000 after purchasing an additional 50 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.